Publications by authors named "Jean Louis Floiras"
Purpose: Several studies suggest that surgical excision of the primary tumor improves survival among patients with stage IV breast cancer at diagnosis. Exclusive locoregional radiotherapy (LRR) is an alternative form of locoregional treatment (LRT) in this setting. We retrospectively studied the impact of LRT on the survival of breast cancer patients with synchronous metastases.
View Article and Find Full Text PDFUse of single MRI and 18F-FDG PET-CT scans in both diagnosis and radiotherapy treatment planning in patients with head and neck cancer: advantage on target volume and critical organ delineation.
Head Neck
April 2009
Article Synopsis
- The study assessed the effectiveness of using MRI and 18F-FDG PET-CT in diagnosing and planning radiotherapy for head and neck cancer in 35 patients.
- The comparison of images from MRI and CT showed a decrease in interobserver variation for parotid glands and target volumes in a significant number of cases.
- Additionally, the application of 18F-FDG PET-CT led to changes in treatment plans for some patients, suggesting it can enhance planning accuracy under specific conditions.
Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score.
Int J Radiat Oncol Biol Phys
November 2007
Purpose: To validate the Radiation Therapy Oncology Group Recursive Partitioning Analysis (RTOG RPA) classification and determine independent prognostic factors, to create a simple and specific prognostic score for patients with brain metastases (BM) from breast carcinoma treated with whole-brain radiotherapy (WBRT).
Methods And Materials: From January 1998 through December 2003, 132 patients with BM from breast carcinoma were treated with WBRT. We analyzed several potential predictors of survival after WBRT: age, Karnofsky performance status, RTOG-RPA class, number of BM, presence and site of other systemic metastases, interval between primary tumor and BM, tumor hormone receptor (HR) status, lymphocyte count, and HER-2 overexpression.
Purpose: Non-Hodgkin's lymphoma of the breast represents 0.04%-0.50% of malignant lesions of the mammary gland.
View Article and Find Full Text PDF